Drug
Imgc936
Imgc936: highest development phase Phase 1/2, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMGC936 NCT04622774 | Phase 1/2 | Advanced Solid Tumor |
Latest
No recent events.
Follow Imgc936 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.